PMID- 21548925
OWN - NLM
STAT- MEDLINE
DCOM- 20110926
LR  - 20211020
IS  - 1756-9966 (Electronic)
IS  - 0392-9078 (Print)
IS  - 0392-9078 (Linking)
VI  - 30
IP  - 1
DP  - 2011 May 6
TI  - Maintenance therapy in NSCLC: why? To whom? Which agent?
PG  - 50
LID - 10.1186/1756-9966-30-50 [doi]
AB  - Maintenance therapy is emerging as a treatment strategy in the management of 
      advanced non small cell lung cancer (NSCLC). Initial trials addressing the 
      question of duration of combination chemotherapy failed to show any overall 
      survival benefit for the prolonged administration over a fixed number of cycles 
      with an increased risk for cumulative toxicity. Nowadays several agents with 
      different ways of administration and a different pattern of toxicity have been 
      formally investigated in the maintenance setting. Maintenance strategies include 
      continuing with an agent already present in the induction regimen or switching to 
      a different one. Taking into consideration that no comparative trials of 
      maintenance with different chemotherapy drugs or targeted agents have been 
      conducted, the choice and the duration of maintenance agents is largely 
      empirical. Furthermore, it is still unknown and it remains an open question if 
      this approach needs to be proposed to every patient in the case of 
      partial/complete response or stable disease after the induction therapy. Here, we 
      critically review available data on maintenance treatment, discussing the 
      possibility to tailor the right treatment to the right patient, in an attempt to 
      optimize costs and benefits of an ever-growing panel of different treatment 
      options.
FAU - Novello, Silvia
AU  - Novello S
AD  - Thoracic Oncology Unit, University of Turin, AOU, San Luigi Orbassano, Italy. 
      silvia.novello@unito.it
FAU - Milella, Michele
AU  - Milella M
FAU - Tiseo, Marcello
AU  - Tiseo M
FAU - Banna, Giuseppe
AU  - Banna G
FAU - Cortinovis, Diego
AU  - Cortinovis D
FAU - Di Maio, Massimo
AU  - Di Maio M
FAU - Garassino, Marina
AU  - Garassino M
FAU - Maione, Paolo
AU  - Maione P
FAU - Martelli, Olga
AU  - Martelli O
FAU - Vavala, Tiziana
AU  - Vavala T
FAU - Bria, Emilio
AU  - Bria E
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20110506
PL  - England
TA  - J Exp Clin Cancer Res
JT  - Journal of experimental & clinical cancer research : CR
JID - 8308647
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Antineoplastic Agents/*therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy
MH  - Clinical Trials as Topic
MH  - Humans
MH  - Lung Neoplasms/*drug therapy
PMC - PMC3113744
EDAT- 2011/05/10 06:00
MHDA- 2011/09/29 06:00
PMCR- 2011/05/06
CRDT- 2011/05/10 06:00
PHST- 2011/02/07 00:00 [received]
PHST- 2011/05/06 00:00 [accepted]
PHST- 2011/05/10 06:00 [entrez]
PHST- 2011/05/10 06:00 [pubmed]
PHST- 2011/09/29 06:00 [medline]
PHST- 2011/05/06 00:00 [pmc-release]
AID - 1756-9966-30-50 [pii]
AID - 10.1186/1756-9966-30-50 [doi]
PST - epublish
SO  - J Exp Clin Cancer Res. 2011 May 6;30(1):50. doi: 10.1186/1756-9966-30-50.